Penumbra, Inc.
HealthcareNYSE:PEN · New York Stock Exchange
+$0.11 today
Vol 0.45M · Avg 0.51M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Earnings Waterfall
Revenue to Net Income
Key Ratios
Analysis
$1.5B of revenue converted into $171.0M of net income for the selected period. Gross margin is 67.4% and net margin is 11.8%, showing how much revenue survives after costs and taxes. EPS is $4.34, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.4B +17.5% | $1.2B +12.9% | $1.1B +25.0% | $847.1M +13.3% | $747.6M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $461.2M +4.9% | $439.6M +17.0% | $375.9M +20.5% | $311.9M +14.6% | $272.2M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $942.4M +24.8% | $755.0M +10.6% | $682.6M +27.5% | $535.2M +12.6% | $475.4M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 67.1% +3.9pp | 63.2% -1.3pp | 64.5% +1.3pp | 63.2% -0.4pp | 63.6% | 9.8% | 28.9% | 38.3% |
| Research & Development | $89.8M -5.3% | $94.8M +12.3% | $84.4M +6.3% | $79.4M -24.1% | $104.6M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $663.4M +15.6% | $574.0M +13.3% | $506.5M +12.6% | $449.7M +18.9% | $378.3M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $753.2M +1.0% | $745.7M +22.4% | $609.1M +15.1% | $529.1M +9.6% | $482.9M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $17.5M -26.3% | $23.7M -13.0% | $27.3M +12.1% | $24.3M +48.2% | $16.4M | $374.2M | $1.2B | $631.8M |
| EBITDA | $222.6M +384.0% | $46.0M -57.7% | $108.6M +262.6% | $30.0M +282.2% | $7.8M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | 15.9% +12.0pp | 3.8% -6.4pp | 10.3% +6.7pp | 3.5% +2.5pp | 1.0% | 5.6% | 46.3% | 42.0% |
| Operating Income | $189.2M +1939.5% | $9.3M -87.4% | $73.6M +1109.3% | $6.1M +181.1% | -$7.5M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | 13.5% +12.7pp | 0.8% -6.2pp | 6.9% +6.2pp | 0.7% +1.7pp | -1.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $0 -100.0% | $13.7M +100.6% | $6.8M +261.9% | $1.9M -34.3% | $2.9M | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 -100.0% | $1.4M -18.5% | $1.7M -0.6% | $1.7M -9.5% | $1.9M | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $15.9M +37.0% | $11.6M +90.0% | $6.1M +378.5% | -$2.2M +27.0% | -$3.0M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | $205.1M +882.9% | $20.9M -73.8% | $79.7M +1946.5% | $3.9M +137.1% | -$10.5M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | 14.6% +12.9pp | 1.7% -5.8pp | 7.5% +7.1pp | 0.5% +1.9pp | -1.4% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $27.4M +300.1% | $6.9M +160.7% | -$11.3M -291.8% | $5.9M +144.9% | -$13.1M | $1.3B | -$1.6B | $745.2M |
| Net Income | $177.7M +1168.1% | $14.0M -84.6% | $91.0M +4643.2% | -$2.0M -137.9% | $5.3M | $4.9B | $4.8B | $4.7B |
| Net Margin | 12.7% +11.5pp | 1.2% -7.4pp | 8.6% +8.8pp | -0.2% -0.9pp | 0.7% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | $5 +1169.4% | $0 -84.8% | $2 +4580.2% | -$0 -137.8% | $0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | $5 +1155.6% | $0 -84.5% | $2 +4485.6% | -$0 -137.8% | $0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $38.9M +0.7% | $38.6M +0.6% | $38.4M +1.5% | $37.8M +2.9% | $36.8M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $39.3M +0.1% | $39.3M +0.1% | $39.2M +3.6% | $37.8M -0.1% | $37.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
DaVita Inc.
NYSE:DVA
$13.47B
Align Technology, Inc.
NASDAQ:ALGN
$12.49B
Globus Medical, Inc.
NYSE:GMED
$10.88B
Baxter International Inc.
NYSE:BAX
$10.71B
Henry Schein, Inc.
NASDAQ:HSIC
$9.32B
Charles River Laboratories International, Inc.
NYSE:CRL
$9.07B
Bio-Rad Laboratories, Inc.
NYSE:BIO
$7.72B
HealthEquity, Inc.
NASDAQ:HQY
$7.36B
Hims & Hers Health, Inc.
NYSE:HIMS
$5.97B
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does PEN generate?
Penumbra, Inc. (PEN) reported $1.40B of revenue in fiscal 2025.
Is PEN profitable?
Penumbra, Inc. (PEN) reported $177.69M of net income, with a net margin of 12.7%.
Explore More
Continue the stock analysis
Jump to another research area for this company.